Cocrystal Pharma, Inc. (COCP )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol COCP
- Company Cocrystal Pharma, Inc.
- Price $1.51
- Changes Percentage 48.04
- Change 0.49
- Day Low $1.36
- Day High $2.03
- Year High $2.67
- Year Low $0.86
- Market Cap $15,476,688
- Price Avg 50 EMA (D) $1.03
- Price Avg 200 EMA (D) $1.23
- Exchange NASDAQ
- Volume 135,319,178
- Average Volume 2,263,335
- Open $1.7
- Previous Close $1.02
- EPS -0.78
- PE -1.94
- Earnings Announcement 2026-04-06 12:00:00
- Shares Outstanding $10,249,462
Company brief: COCRYSTAL PHARMA, INC. (COCP )
- Healthcare
- Biotechnology
- Dr. Sam Lee Ph.D.
- https://www.cocrystalpharma.com
- US
- N/A
- 02-22-2012
- US19188J4094
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
COCP Corporation News
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
globenewswire.com -- Phase 1b norovirus challenge study is underway at Emory University School of Medicine CDI-988 is the first oral antiviral candidate being developed for norovirus treatment and prevention No approved t...